Trial Profile
A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Davunetide (Primary)
- Indications Alzheimer's disease; Corticobasal degeneration; Dementia; Parkinsonian disorders; Progressive supranuclear palsy; Tauopathies
- Focus Adverse reactions
- 23 Mar 2018 Status changed from active, no longer recruiting to completed.
- 05 Dec 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
- 05 Dec 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.